REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.

This important study describes a first-in-human trial of autologous p63+ stem cells in patients with idiopathic pulmonary fibrosis, a lethal condition for which effective treatments are lacking. The ...

("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, yesterday presented data from the TakeAim ...

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced the receipt of FDA clearance for testing AIV001 (axitinib) by intradermal injection with their formulation in facial skin.

TransThera Sciences Nanjing, Inc. (the "TransThera") announced the poster presentation at the 2024 European Society For Medical Oncology (ESMO) Asia Congress to discuss the clinical study of ...